Cardiovascular Manifestations of COVID-19

Conditions:   Cardiovascular Diseases;   COVID Intervention:   Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values Sponsor:   Memorial Hermann Health System Recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

NEW BRUNSWICK, NJ, May 27, 2020 — The Janssen Pharmaceutical Companies of Johnson &Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new pediatric formulation of SIRTURO® (bedaquiline). SIRTURO® is now indicated for use as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR‑TB). In the U.S., the medicine should be reserved for use when an effective treatment regimen cannot otherwise be provided. This indication received accelera...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Among candidate drugs to treat COVID-19, the combination of hydroxychloroquine (HCQ) and azithromycin (AZ) has received intense attention. Even if the efficacy of this combination is under evaluation, clinicians have begun to use it largely. As these medications are known to prolong QT interval, we analyzed serial electrocardiograms (ECG) performed in patients hospitalized for COVID-19 pneumonia and treated with HCQ + AZ.50 consecutive patients received the combination of HCQ (600mg/d for 10 days) and AZ (500mg Day 1 and 250mg daily days 2 to 5).
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Brief Report Source Type: research
Hydroxychloroquine and azithromycin combination therapy is often prescribed for coronavirus disease 2019 (COVID-19). Electrocardiographic (ECG) monitoring is warranted because both medications cause corrected QT-interval (QTc) prolongation. Whether QTc duration significantly varies during the day, potentially requiring multiple ECGs, remains to be established.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Short communication Source Type: research
Source: U.S. Food and Drug Administration (FDA). Published: 5/14/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the G Medical VSMS ECG Patch. The VSMS Patch is authorized for emergency use in the hospital setting for remote monitoring of the QT interval of an electrocardiogram (ECG) in general care (i.e., not in the intensive care unit) patients who are 18 years of age or older and are undergoing treatment for COVID-19 using drugs that can prolong the QT intervals and may cause life-threatening arrhythmias ( e.g., hydroxychlor...
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - Category: International Medicine & Public Health Source Type: news
Many COVID-19 trials have not looked at ECGs, either to exclude people at highest risk for a life-threatening cardiac arrhythmia or to flag people who achieve a dangerous QTc interval on treatment.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
Written by Pendell MeyersA man in his 50s with HTN, HLD, obesity, and restrictive lung disease presented with shortness of breath worsening over the past 3 days. He also had a cough and subjective fevers. He denied chest pain. His vitals were within normal limits.Here is his triage ECG (no baseline available):What do you think?Findings: - sinus rhythm at about 100 bpm - STE in I and aVL (meets STEMI criteria) - hint of STD in III and aVF - STD in V1 and V2 - hyperacute T-waves in I and aVL (with reciprocal negative hyperacute T in III)Interpretation:This is definitive evidence of acute transmural i...
Source: Dr. Smith's ECG Blog - Category: Cardiology Authors: Source Type: blogs
LifeSignals, based in Fremont, California, announced that it received the CE Mark for its LifeSignals ECG Remote Monitoring Patch. The patch, integrated with a remote monitoring platform, is designed as a continuous electrocardiography (ECG) and hear...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiology Source Type: blogs
Authors: Scoppettuolo G, Biasucci DG, Pittiruti M Abstract The 2020 COVID pandemic has forced everyone to update the usual medical procedures and adapt them to a new situation characterized by a high risk of contamination of the health operator. The placement of a venous access device is no exception. In the experience of the vascular access team of our hospital, hit by the COVID epidemic in March 2020, the safety of both the patient and the staff can be ensured by an insertion bundle of few smart strategies, which include choice of long dwelling peripheral catheters (midline catheters) rather than short venous can...
Source: The Journal of Vascular Access - Category: Surgery Tags: J Vasc Access Source Type: research
We report the case of a 60-year-old woman without any cardiac history who developed right bundle brunch block and critically prolonged corrected electrocardiographic QT interval (QTc 631 ms) after treatment for 3 days with HCQ, which resolved on discontinuation of the medication. This case highlights a significant and potentially life-threatening complication of HCQ use. PMID: 32383430 [PubMed - as supplied by publisher]
Source: The American Journal of Tropical Medicine and Hygiene - Category: Tropical Medicine Authors: Tags: Am J Trop Med Hyg Source Type: research
CONCLUSION: "Off-label" use of treatments in COVID-19 increases the risk of cardiac ADRs, some of them avoidable. Even if these drugs are perceived as familiar, they are used in patients with added risk factors caused by infection. Precautions should be taken to mitigate the risk, even if they will be proven efficacious. PMID: 32418730 [PubMed - as supplied by publisher]
Source: Therapie - Category: Psychiatry & Psychology Authors: Tags: Therapie Source Type: research
More News: Cardiology | Cardiovascular | COVID-19 | Electrocardiogram | Heart | Laboratory Medicine | Research